Folate, Vitamin D3

Folixate ™ is indicated for dietary management of patients with unique nutritional needs requiring increased folate level and Vitamin D supplementation. Folixate™ can be taken by women of childbearing age, pregnant women, and lactating and nonlactating mothers.

Take one tablet daily or as directed by a licensed healthcare practitioner.

This product is contraindicated in patients with a known hypersensitivity to any of the ingredients. Folixate ™ is contraindicated in patients with hypercalcemia, malabsorption syndrome, abnormal sensitivity to the toxic effects of Vitamin D, and hypervitaminosis D.

WARNINGS AND PRECAUTIONS Tell your doctor if you have: kidney problems, thyroid disease. This medication should be used as directed during pregnancy or while breast-feeding. Consult your doctor about the risks and benefits. Folate alone is improper therapy in the treatment of pernicious anemia and other megaloblastic anemias where Vitamin B12 is deficient. Folate in doses above 0.1 mg daily may obscure pernicious anemia in that hematologic remission can occur while neurological manifestations progress.

Allergic sensitization has been reported following both oral and parenteral administration of folate. You should call your doctor for medical advice about serious adverse events. To report adverse side effects or to obtain product information, contact PureTek Corporation, at 1-877-921-7873.

Folixate ™ is an orally administered prescription folate product for the dietary management of patients with unique nutritional needs requiring increased folate level and Vitamin D supplementation due to Vitamin D deficiency. Folixate ™ should be administered under the supervision of a licensed healthcare practitioner. Each tablet contains: Folate (as L-5-Methyltetrahydrofolate calcium salt)......1700 mcg DFE (1000 mcg of L-5-methylfolate) Vitamin D3 (as Cholecalciferol)………....................125 mcg (5000 IU) Each tablet contains the following inactive ingredients: Lactose Monohydrate, Magnesium Stearate, Microcrystalline Cellulose, Sodium Starch Glycolate, Vegetable Stearic Acid.

The in vivo synthesis of the major biologically active metabolites of Vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1,25-dihydroxyvitamin D). Vitamin D metabolites promote the active absorption of calcium and phosphorus by the small intestine, thus elevating serum calcium and phosphate levels sufficiently to permit bone mineralization. Vitamin D metabolites also mobilize calcium and phosphate from bone and probably increase the reabsorption of calcium and perhaps also of phosphate by the renal tubules. There is a time lag of 10 to 24 hours between the administration of Vitamin D and the initiation of its action in the body due to the necessity of synthesis of the active metabolites in the liver and kidneys. Parathyroid hormone is responsible for the regulation of this metabolism in the kidneys.

STORAGE KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Protect from heat, light and moisture. Tamper Evident: Do not use if seal is broken or missing.